№ lp_1_2_59496
File format: docx Character count: 10937 File size: 44 KB
Year: 2019
Region / City: Australia
Topic: Opiate Dependence, Pharmaceutical Approval
Document Type: Application for Pharmaceutical Listing
Organization / Institution: PBAC, TGA
Author: Indivior Pty Ltd
Target Audience: Medical professionals, Pharmaceutical regulatory bodies
Effective Period: From July 2019
Approval Date: 18 July 2019
Amendment Date: 17 July 2019
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Opiate Substitution Treatment Program Community Relations Plan
Year: 2021
Region / City: Washington State
Subject: Opiate Substitution Treatment
Document Type: Community Relations Plan
Agency: Washington State Department of Social and Health Services
Author: Jessica Blose, DBHR Certification Policy Manager
Target Audience: Program administrators, community stakeholders
Period of Effect: Ongoing
Approval Date: 2021
Date of Changes: N/A
Clinical Opiate Withdrawal Scale (COWS)
Note: Date and time
Mild withdrawal: score 5-12
Moderate withdrawal: 13-24
Moderately severe withdrawal: 25-36
Severe withdrawal: more than 36
Reference: Wesson, D. R., & Ling, W. (2003). The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs, 35(2), 253–9.
Buprenorphine Resources for Patients: Guide to Safely Taking Buprenorphine at Home
Language: English
Topic: Opioid use disorder treatment
Type of document: Patient medical guidance
Medication: Buprenorphine
Related medication: Suboxone
Dosage information: 4 mg, 8 mg, 12 mg, maximum 16 mg on Day 2
Administration method: Sublingual film or tablet
Treatment period covered: Day 1 and Day 2 initiation
Target audience: Patients beginning buprenorphine treatment at home
Clinical follow-up: Required clinic visit on Day 2
Safety instructions: Withdrawal-based induction and dosage limits
Context: Emergency department discharge and outpatient follow-up care
Topics: Sublocade Opiate Buprenorphine